365 related articles for article (PubMed ID: 34028782)
41. Molecular gene signature and prognosis of non-small cell lung cancer.
Huang P; Cheng CL; Chang YH; Liu CH; Hsu YC; Chen JS; Chang GC; Ho BC; Su KY; Chen HY; Yu SL
Oncotarget; 2016 Aug; 7(32):51898-51907. PubMed ID: 27437769
[TBL] [Abstract][Full Text] [Related]
42. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.
Potti A; Mukherjee S; Petersen R; Dressman HK; Bild A; Koontz J; Kratzke R; Watson MA; Kelley M; Ginsburg GS; West M; Harpole DH; Nevins JR
N Engl J Med; 2006 Aug; 355(6):570-80. PubMed ID: 16899777
[TBL] [Abstract][Full Text] [Related]
43. Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma.
Liu Z; Wan Y; Qiu Y; Qi X; Yang M; Huang J; Zhang Q
Int J Med Sci; 2020; 17(10):1393-1405. PubMed ID: 32624696
[No Abstract] [Full Text] [Related]
44. A prognostic 4-gene expression signature for squamous cell lung carcinoma.
Li J; Wang J; Chen Y; Yang L; Chen S
J Cell Physiol; 2017 Dec; 232(12):3702-3713. PubMed ID: 28160492
[TBL] [Abstract][Full Text] [Related]
45. Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes.
Zheng Z; Deng W; Yang J
Biomed Res Int; 2020; 2020():8832739. PubMed ID: 33490259
[TBL] [Abstract][Full Text] [Related]
46. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
47. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
Zhou W; Zhang W
BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504
[TBL] [Abstract][Full Text] [Related]
48. Identification of 5 Gene Signatures in Survival Prediction for Patients with Lung Squamous Cell Carcinoma Based on Integrated Multiomics Data Analysis.
Ma H; Tong L; Zhang Q; Chang W; Li F
Biomed Res Int; 2020; 2020():6427483. PubMed ID: 32596344
[TBL] [Abstract][Full Text] [Related]
49. Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma.
Zhang J; Bing Z; Yan P; Tian J; Shi X; Wang Y; Yang K
J Gene Med; 2019 Aug; 21(8):e3105. PubMed ID: 31215090
[TBL] [Abstract][Full Text] [Related]
50. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.
Song J; Tian J; Zhang L; Qu X; Qian W; Zheng B; Zhang L; Zhao J; Niu M; Zhou M; Cui L; Liu Y; Zhao M
Eur Radiol; 2019 May; 29(5):2388-2398. PubMed ID: 30643941
[TBL] [Abstract][Full Text] [Related]
51. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
[TBL] [Abstract][Full Text] [Related]
52. A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.
Miao TW; Yang DQ; Chen FY; Zhu Q; Chen X
Biosci Rep; 2022 Aug; 42(8):. PubMed ID: 35866375
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of eight immune-related genes on survival in patients with lung squamous cell carcinoma.
Wu H; Huang S; Zhuang W; Qiao G
Biomark Med; 2021 Mar; 15(4):295-306. PubMed ID: 33590774
[No Abstract] [Full Text] [Related]
54. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
[TBL] [Abstract][Full Text] [Related]
55. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
56. Survival and risk model for stage IB non-small cell lung cancer.
Padilla J; Calvo V; Peñalver JC; Zarza AG; Pastor J; Blasco E; París F
Lung Cancer; 2002 Apr; 36(1):43-8. PubMed ID: 11891032
[TBL] [Abstract][Full Text] [Related]
57. Expression profiling defines a recurrence signature in lung squamous cell carcinoma.
Larsen JE; Pavey SJ; Passmore LH; Bowman R; Clarke BE; Hayward NK; Fong KM
Carcinogenesis; 2007 Mar; 28(3):760-6. PubMed ID: 17082175
[TBL] [Abstract][Full Text] [Related]
58. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
Lu Y; Wang L; Liu P; Yang P; You M
PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
[TBL] [Abstract][Full Text] [Related]
59. Construction and validation of a prognostic model based on ten signature cell cycle-related genes for early-stage lung squamous cell carcinoma.
Zhang C; Huang Y; Fang C; Liang Y; Jiang D; Li J; Ma H; Jiang W; Feng Y
Cancer Biomark; 2023; 36(4):313-326. PubMed ID: 36938730
[TBL] [Abstract][Full Text] [Related]
60. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
